Patent 11179426 was granted and assigned to Kibow Biotech Inc on November, 2021 by the United States Patent and Trademark Office.
A delayed-release composition composed of a Lactobacillus bacterium, Bifidobacterium longum, Streptococcus thermophilus, inulin and xylooligosaccharide is provided for use in reducing nitrogenous waste products in the blood and treating renal failure.